BeOne Medicines (6160 HK)

502

Analysis

Health Care • Switzerland

BeOne Medicines is a global oncology biotechnology company focused on the discovery, development, and commercialization of cancer medicines. Its portfolio includes commercial-stage products like BRUKINSA, TEVIMBRA, and PARTRUVIX, which target various blood cancers and solid tumors. The company was founded in 2010 and is headquartered in Basel, Switzerland.

Refresh

bullish•BeOne Medicines

•05 Aug 2026 09:36

Primer: BeOne Medicines (6160 HK) - Aug 2026

BeOne Medicines is rapidly transitioning into a commercial-stage global oncology powerhouse, driven by the strong performance of its flagship...

αSK Primers

107 Views

bullish•BeOne

•05 Aug 2026 07:54

Primer: BeOne (ONC US) - Aug 2026

BeOne is rapidly transitioning into a profitable, commercial-stage biopharmaceutical company, driven by the blockbuster success of its BTK...

αSK Primers

119 Views

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00